Drugs / FLX-787
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03196375 | Jul 2017 → Jul 2018 | motor neuron disorder | Flex Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLX-787 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03196375 ↗ |
| Route | Oral | “orally disintegrating tablet” NCT03196375 ↗ |